Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 17, 2016, Pages 4777-4782

  Schulze Topphoff, Ulf ^a,b   Varrin Doyer, Michel ^a,b,f   Pekarek, Kara ^a,b   Spencer, Collin M ^a,b   Shetty, Aparna ^a,b   Sagan, Sharon A ^a,b   Cree, Bruce A C ^a   Sobel, Raymond A ^c   Wipke, Brian T ^d   Steinman, Lawrence ^e   Scannevin, Robert H ^d   Zamvil, Scott S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BIOGEN   (United States)

^e STANFORD UNIVERSITY   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dimethyl fumarate; EAE; M2 monocytes; Multiple sclerosis; Nrf2

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; GAMMA INTERFERON; INTERLEUKIN 17; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN[35-55]; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; NFE2L2 PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNIZATION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MONOCYTE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; MALE; ORAL DRUG ADMINISTRATION; SPLEEN;

ADAPTIVE IMMUNITY; ADMINISTRATION, ORAL; ANIMALS; CELLS, CULTURED; DIMETHYL FUMARATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED C57BL; NF-E2-RELATED FACTOR 2; SPLEEN;

EID: 84964757913     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1603907113     Document Type: Article

References (42)

1. Lehmann JC, et al. (2007) Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase J Invest Dermatol 127(4):835-845.
2. Mrowietz U, Asadullah K (2005) Dimethylfumarate for psoriasis: More than a dietary curiosity. Trends Mol Med 11(1):43-48.
3. Linker RA, et al. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3):678-692.
4. Scannevin RH, et al. (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 341(1):274-284.
5. Itoh K, et al. (2003) Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 8(4):379-391.
6. Itoh K, et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236(2):313-322.
7. Nguyen T, Sherratt PJ, Nioi P, Yang CS, Pickett CB (2005) Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem 280(37):32485-32492.
8. Gold R, et al.; DEFINE Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098-1107.
9. Fox RJ, et al.; CONFIRM Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087-1097.
10. Gillard GO, et al. (2015) DMF, but not other fumarates, inhibits NF-?B activity in vitro in an Nrf2-independent manner. J Neuroimmunol 283:74-85.
11. Ghoreschi K, et al. (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208(11):2291-2303.
12. Thimmulappa RK, et al. (2006) Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 116(4):984-995.
13. Thimmulappa RK, et al. (2006) Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-imidazolide. Biochem Biophys Res Commun 351(4):883-889.
14. Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA (2010) The absence of the pro-Antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol Sci 114(2):237-246.
15. Rockwell CE, Zhang M, Fields PE, Klaassen CD (2012) Th2 skewing by activation of Nrf2 in CD4+ T cells. J Immunol 188(4):1630-1637.
16. Croxford AL, Kurschus FC, Waisman A (2011) Mouse models for multiple sclerosis: Historical facts and future implications. Biochim Biophys Acta 1812(2):177-183.
17. Zhu B, et al. (2007) CD11b+Ly-6Chi suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 179(8):5228-5237.
18. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS (2015) Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2(3):e76.
19. Longbrake EE, et al. (2015) Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler, pii: 1352458515608961.
20. Molnarfi N, et al. (2013) MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 210(13):2921-2937.
21. Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK (2006) Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 116(9):2393-2402.
22. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A (2006) Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 116(9):2385-2392.
23. Brennan MS, et al. (2015) Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. PLoS One 10(3):e0120254.
24. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89-116.
25. Brück W, et al. (2013) Therapeutic decisions in multiple sclerosis: Moving beyond efficacy. JAMA Neurol 70(10):1315-1324.
26. Metz I, et al. (2015) Glial cells express nuclear nrf2 after fumarate treatment for multiple sclerosis and psoriasis. Neurol Neuroimmunol Neuroinflamm 2(3):e99.
27. Licht-Mayer S, et al. (2015) Cell type-specific Nrf2 expression in multiple sclerosis lesions. Acta Neuropathol 130(2):263-277.
28. Tsai JJ, et al. (2013) Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol 15(3):309-316.
29. Hauser SL, et al.; HERMES Trial Group (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676-688.
30. Bittner S, et al. (2014) Effects of glatiramer acetate in a spontaneous model of autoimmune neuroinflammation. Am J Pathol 184(7):2056-2065.
31. Aharoni R, Teitelbaum D, Sela M, Arnon R (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 94(20):10821-10826.
32. Stüve O, et al. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116(4):1037-1044.
33. Weber MS, et al. (2007) Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13(8):935-943.
34. Tang H, Lu JY, Zheng X, Yang Y, Reagan JD (2008) The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun 375(4):562-565.
35. Chen H, et al. (2014) Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest 124(5):2188-2192.
36. Parodi B, et al. (2015) Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol 130(2):279-295.
37. Kappos L, et al.; BG-12 Phase IIb Study Investigators (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372(9648): 1463-1472.
38. Sheikh SI, et al. (2013) Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther 35(10):1582-1594.e9.
39. Bettelli E, et al. (2003) Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 197(9): 1073-1081.
40. Litzenburger T, et al. (1998) B lymphocytes producing demyelinating autoantibodies: Development and function in gene-targeted transgenic mice. J Exp Med 188(1): 169-180.
41. Schulze-Topphoff U, et al. (2009) Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 15(7):788-793.
42. Kuchroo VK, et al. (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 80(5):707-718.